0001493152-22-035990.txt : 20221220
0001493152-22-035990.hdr.sgml : 20221220
20221220160533
ACCESSION NUMBER: 0001493152-22-035990
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221216
FILED AS OF DATE: 20221220
DATE AS OF CHANGE: 20221220
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Paulsen Gisela
CENTRAL INDEX KEY: 0001807104
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37648
FILM NUMBER: 221474759
MAIL ADDRESS:
STREET 1: 5505 ENDEAVOR LANE
CITY: MADISON
STATE: WI
ZIP: 53719
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Oncocyte Corp
CENTRAL INDEX KEY: 0001642380
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 271041563
STATE OF INCORPORATION: CA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
BUSINESS PHONE: 949-409-7600
MAIL ADDRESS:
STREET 1: 15 CUSHING
CITY: IRVINE
STATE: CA
ZIP: 92618
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20200213
FORMER COMPANY:
FORMER CONFORMED NAME: Oncocyte Corp
DATE OF NAME CHANGE: 20200205
FORMER COMPANY:
FORMER CONFORMED NAME: OncoCyte Corp
DATE OF NAME CHANGE: 20150513
4
1
ownership.xml
X0306
4
2022-12-16
0
0001642380
Oncocyte Corp
OCX
0001807104
Paulsen Gisela
15 CUSHING
IRVINE
CA
92618
0
1
0
0
Former President and COO
Common Stock, no par value
2022-12-01
4
D
0
175000
0
D
366500
D
Option to Purchase Common Stock
3.42
2022-12-16
4
D
0
171875
0
D
Common Stock
171875
203125
D
Option to Purchase Common Stock
1.15
2022-12-16
4
D
0
70313
0
D
Common Stock
70313
54687
D
Option to Purchase Common Stock
1.15
2022-12-16
4
D
0
125000
0
D
Common Stock
125000
0
D
The restricted stock units were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining restricted stock units immediately vested on December 16, 2022.
The options were forfeited by mutual agreement of the Reporting Person and the Issuer in connection with a severance agreement entered into as a result of the Reporting Person's resignation as an officer and director of the Issuer on December 16, 2022. Any remaining options immediately vested and became exercisable as of December 16, 2022.
/s/ Gisela Paulsen
2022-12-20